StreetInsider.com News Articles

Monte Rosa Therapeutics (GLUE) PT Raised to $40 at Jefferies

Mon, 27 Jul 2026 06:41:01 -0400

Jefferies analyst Faisal Khurshid raised the price target on Monte Rosa Therapeutics (NASDAQ: GLUE) to $40.00 (from $30.00) while maintaining a Buy rating.

The analyst comments "Topline data for NVO's ZEUS study of IL-6 ziltivekimab in CKD/ASCVD is due in 3Q. Data has impt readthru addressing residual inflammation in ASCVD, impacting the space as a whole incl GLUE's NEK7 degrader MRT-8102. Based on our extensive work, we expect high PoS in ZEUS (est ~66% PoS on MACE ep w/ base case HR 0.83). Infection risk is the key unknown based on MOA precedent and our KOL checks. We like risk/reward on

Monte Rosa Therapeutics (GLUE) PT Raised to $40 at Jefferies

Mon, 27 Jul 2026 06:41:01 -0400

Jefferies analyst Faisal Khurshid raised the price target on Monte Rosa Therapeutics (NASDAQ: GLUE) to $40.00 (from $30.00) while maintaining a Buy rating.

Form 4 Monte Rosa Therapeutics, For: Jul 16 Filed by: Warmuth Markus

Fri, 17 Jul 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260717/26784340.html

Form 4 Monte Rosa Therapeutics, For: Jul 16 Filed by: Warmuth Markus

Fri, 17 Jul 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260717/26784340.html

Form 4 Monte Rosa Therapeutics, For: Jul 15 Filed by: Champoux Jennifer

Thu, 16 Jul 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260716/26779779.html

Form 4 Monte Rosa Therapeutics, For: Jul 15 Filed by: Champoux Jennifer

Thu, 16 Jul 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260716/26779779.html

Form 144 Monte Rosa Therapeutics, Filed by: Warmuth Markus

Thu, 16 Jul 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260716/26779663.html

Form 144 Monte Rosa Therapeutics, Filed by: Warmuth Markus

Thu, 16 Jul 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260716/26779663.html

Form 144 Monte Rosa Therapeutics, Filed by: Champoux Jennifer

Wed, 15 Jul 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260715/26774259.html

Form 144 Monte Rosa Therapeutics, Filed by: Champoux Jennifer

Wed, 15 Jul 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260715/26774259.html

Form SCHEDULE 13G/A Monte Rosa Therapeutics, Filed by: PRICE T ROWE ASSOCIATES INC /MD/

Wed, 08 Jul 2026 11:29:00 -0400

si-local-file:///var/storage/secattach/20260708/26746212.html

Form SCHEDULE 13G/A Monte Rosa Therapeutics, Filed by: PRICE T ROWE ASSOCIATES INC /MD/

Wed, 08 Jul 2026 11:29:00 -0400

si-local-file:///var/storage/secattach/20260708/26746212.html

Form 4 Monte Rosa Therapeutics, For: Jul 06 Filed by: Townson Sharon

Tue, 07 Jul 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260707/26742335.html

Form 4 Monte Rosa Therapeutics, For: Jul 06 Filed by: Townson Sharon

Tue, 07 Jul 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260707/26742335.html

Form 4 Monte Rosa Therapeutics, For: Jul 01 Filed by: Behbahani Ali

Mon, 06 Jul 2026 17:57:00 -0400

si-local-file:///var/storage/secattach/20260706/26736854.html

Form 4 Monte Rosa Therapeutics, For: Jul 01 Filed by: Behbahani Ali

Mon, 06 Jul 2026 17:57:00 -0400

si-local-file:///var/storage/secattach/20260706/26736854.html

Form SCHEDULE 13D/A Monte Rosa Therapeutics, Filed by: New Enterprise Associates 17, L.P.

Mon, 06 Jul 2026 17:52:00 -0400

si-local-file:///var/storage/secattach/20260706/26736836.html

Form SCHEDULE 13D/A Monte Rosa Therapeutics, Filed by: New Enterprise Associates 17, L.P.

Mon, 06 Jul 2026 17:52:00 -0400

si-local-file:///var/storage/secattach/20260706/26736836.html

Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 02 Jul 2026 16:01:00 -0400

BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the grant of inducement equity awards to three newly hired non-executive employees as a material inducement to commencing their employment with the Company.

The employees received, in the aggregate, non-qualified stock options to purchase 18,025 shares of Monte Rosa Therapeutics common stock, par value $0.0001 per share, with an exercise price per share equal to the closing price of $24.02 as reported by Nasdaq on July 1, the effective date of the

Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 02 Jul 2026 16:01:00 -0400

Form 4 Monte Rosa Therapeutics, For: Jun 30 Filed by: Janku Filip

Wed, 01 Jul 2026 16:58:00 -0400

si-local-file:///var/storage/secattach/20260701/26721808.html

Form 4 Monte Rosa Therapeutics, For: Jun 30 Filed by: Janku Filip

Wed, 01 Jul 2026 16:58:00 -0400

si-local-file:///var/storage/secattach/20260701/26721808.html

Form 144 Monte Rosa Therapeutics, Filed by: Janku Filip

Tue, 30 Jun 2026 16:38:00 -0400

si-local-file:///var/storage/secattach/20260630/26714255.html

Form 144 Monte Rosa Therapeutics, Filed by: Janku Filip

Tue, 30 Jun 2026 16:38:00 -0400

si-local-file:///var/storage/secattach/20260630/26714255.html

Form 4 Monte Rosa Therapeutics, For: Jun 29 Filed by: Manning Anthony M.

Tue, 30 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260630/26713565.html